Johnson & Johnson (NYSE:JNJ) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: October 2, 2016
Zacks Investment Research has downgraded Johnson & Johnson (NYSE:JNJ) to Sell in a statement released on 09/28/2016.
On 9/27/2016, Vetr Inc. released a statement on Johnson & Johnson (NYSE:JNJ) upped the target price from $0.00 to $123.13 that suggested an upside of 0.05%.
Yesterday Johnson & Johnson (NYSE:JNJ) traded 0.73% higher at $119.22. The company’s 50-day moving average is $119.23 and its 200-day moving average is $116.66. The last stock price is up 1.26% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 7,941,065 shares of JNJ traded hands, up from an average trading volume of 6,259,060
Recent Performance Chart
Johnson & Johnson has 52 week low of $92.58 and a 52 week high of $126.07 with a PE ratio of 22.01 and has a market capitalization of $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 18 brokerages have issued a ratings update on the company. The average stock price target is $117.44 with 0 brokerages rating the stock a strong buy, 0 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
Brief Synopsis On Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on over five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.